News Headlines Article

FTC Takes Aim At Generics Pay for Delay
HC Pro

A top competition priority this year at the Federal Trade Commission (FTC) is to stop “pay-for-delay” agreements between branded and generic drug manufacturers, FTC Chairman Jon Leibowitz told the House Judiciary Subcommittee on Courts and Competition Policy on Tuesday.

According to newly released agency data, branded and generic drug companies entered into 21 “suspect patent litigation settlements” involving compensation in the first nine months of fiscal 2010 alone. This surpassed the total for all of fiscal 2009, he said.